BLFS icon

BioLife Solutions

26.28 USD
+0.69
2.7%
At close Updated Sep 18, 4:00 PM EDT
Pre-market
After hours
26.28
0.00
0%
1 day
2.7%
5 days
-1.17%
1 month
7.27%
3 months
22.12%
6 months
3.75%
Year to date
0.38%
1 year
10.79%
5 years
-3.42%
10 years
1,083.78%
 

About: BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Employees: 159

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

57% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 51

32% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 25

3% more funds holding

Funds holding: 189 [Q1] → 194 (+5) [Q2]

2.49% more ownership

Funds ownership: 102.53% [Q1] → 105.02% (+2.49%) [Q2]

5% less capital invested

Capital invested by funds: $1.13B [Q1] → $1.07B (-$51.1M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

67% less call options, than puts

Call options by funds: $6K | Put options by funds: $18K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$32
22% upside
Avg. target
$32
22% upside
High target
$32
22% upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
$32
Buy
Maintained
8 Aug 2025

Financial journalist opinion

Positive
Zacks Investment Research
20 days ago
Does BioLife Solutions (BLFS) Have the Potential to Rally 25.6% as Wall Street Analysts Expect?
The consensus price target hints at a 25.6% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does BioLife Solutions (BLFS) Have the Potential to Rally 25.6% as Wall Street Analysts Expect?
Negative
Zacks Investment Research
1 month ago
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical products industry sees steady demand, but tariffs & policy headwinds keep growth under pressure in 2025. NVST, BLFS, INFU and MRMD reflect the favorable fundamentals.
4 Medical Product Stocks to Watch From a Challenging Industry
Positive
Zacks Investment Research
1 month ago
BioLife Solutions (BLFS) Upgraded to Strong Buy: Here's Why
BioLife Solutions (BLFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioLife Solutions (BLFS) Upgraded to Strong Buy: Here's Why
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict a 39.92% Upside in BioLife Solutions (BLFS): Here's What You Should Know
The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 39.92% Upside in BioLife Solutions (BLFS): Here's What You Should Know
Neutral
Seeking Alpha
1 month ago
BioLife Solutions, Inc. (BLFS) Q2 2025 Earnings Call Transcript
BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Roderick de Greef - CEO & Chairman Troy Wichterman - Chief Financial Officer Conference Call Participants Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division Chad M. Wiatrowski - TD Cowen, Research Division Matthew Jay Stanton - Jefferies LLC, Research Division Yi Chen - H.C.
BioLife Solutions, Inc. (BLFS) Q2 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
1 month ago
BioLife Solutions, Inc. (BLFS) Reports Break-Even Earnings for Q2
BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.06 per share a year ago.
BioLife Solutions, Inc. (BLFS) Reports Break-Even Earnings for Q2
Neutral
PRNewsWire
1 month ago
BioLife Solutions Reports Second Quarter 2025 Financial Results
Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62%  and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue Raises full-year 2025 revenue guidance to $100.0 million - $103.0 million, and full-year 2025 Cell Processing revenue guidance to $91.0 million - $93.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.
BioLife Solutions Reports Second Quarter 2025 Financial Results
Neutral
PRNewsWire
1 month ago
BioLife Solutions Makes Strategic Investment in Pluristyx
BOTHELL, Wash. , July 28, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced that as part of a larger round of financing it has purchased $2 million of convertible notes in Pluristyx, Inc. ("Pluristyx"), a Seattle based developer of innovative induced pluripotent stem cell (iSPC) based products for cell therapy developers.
BioLife Solutions Makes Strategic Investment in Pluristyx
Neutral
PRNewsWire
1 month ago
BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025
BOTHELL, Wash. , July 24, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025.
BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025
Positive
Zacks Investment Research
3 months ago
How Much Upside is Left in BioLife Solutions (BLFS)? Wall Street Analysts Think 41.72%
The average of price targets set by Wall Street analysts indicates a potential upside of 41.7% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in BioLife Solutions (BLFS)? Wall Street Analysts Think 41.72%
Charts implemented using Lightweight Charts™